Istari Oncology

Istari Oncology, Inc. is a clinical-stage biotechnology company developing innovative immunotherapies for the treatment of patients with solid tumors. Istari has built a passionate and experienced leadership team focused on clinical trial strategy and driving execution, while seeking opportunities to establish partnerships with world-leading cancer centers and oncology biotechnology companies. Our lead product is lerapolturev, an investigational immunotherapy based on the Sabin oral poliovirus vaccine, genetically engineered to eliminate neurotoxicity and harness multiple unique mechanisms of action to activate systemic anti-tumor responses against cancer.